Loading...

Agios Pharmaceuticals

DB:8AP
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8AP
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The last earnings update was 63 days ago. More info.


Add to Portfolio Compare Print
8AP Share Price and Events
7 Day Returns
-12%
DB:8AP
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-30.9%
DB:8AP
-9.2%
DE Biotechs
-6.7%
DE Market
8AP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Agios Pharmaceuticals (8AP) -12% -14.1% 1.2% -30.9% 4.3% 52.7%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 8AP underperformed the Biotechs industry which returned -9.2% over the past year.
  • 8AP underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
8AP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Agios Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Agios Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Agios Pharmaceuticals.

DB:8AP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:8AP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:8AP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Agios Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:8AP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -358.00 Analyst x2 -331.45
2020 -335.00 Analyst x2 -287.16
2021 -197.00 Analyst x2 -156.35
2022 108.00 Analyst x2 79.36
2023 411.50 Analyst x2 279.94
2024 690.78 Est @ 67.87% 435.09
2025 1,019.44 Est @ 47.58% 594.49
2026 1,359.65 Est @ 33.37% 734.09
2027 1,678.21 Est @ 23.43% 838.90
2028 1,954.59 Est @ 16.47% 904.60
Present value of next 10 years cash flows $3,091.51
DB:8AP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $1,954.59 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$25,177.41
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $25,177.41 ÷ (1 + 8.01%)10
$11,652.32
DB:8AP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $3,091.51 + $11,652.32
$14,743.83
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $14,743.83 / 58.40
$252.48
DB:8AP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:8AP represents 0.88315x of NasdaqGS:AGIO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88315x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 252.48 x 0.88315
€222.98
Value per share (EUR) From above. €222.98
Current discount Discount to share price of €49.43
= -1 x (€49.43 - €222.98) / €222.98
77.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Agios Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €49.43 vs Future cash flow value of €222.98
Current Discount Checks
For Agios Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Agios Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Agios Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Agios Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Agios Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8AP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-6.03
NasdaqGS:AGIO Share Price ** NasdaqGS (2019-04-18) in USD $55.97
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Agios Pharmaceuticals.

DB:8AP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AGIO Share Price ÷ EPS (both in USD)

= 55.97 ÷ -6.03

-9.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agios Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Agios Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Agios Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:8AP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
44.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Agios Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Agios Pharmaceuticals's assets?
Raw Data
DB:8AP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $11.81
NasdaqGS:AGIO Share Price * NasdaqGS (2019-04-18) in USD $55.97
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:8AP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AGIO Share Price ÷ Book Value per Share (both in USD)

= 55.97 ÷ 11.81

4.74x

* Primary Listing of Agios Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agios Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Agios Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Agios Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Agios Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
44.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Agios Pharmaceuticals expected to grow at an attractive rate?
  • Agios Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Agios Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Agios Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8AP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8AP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 44.1%
DB:8AP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts 41.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8AP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8AP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 900 269 269 8
2022-12-31 619 32 27 8
2021-12-31 360 -247 -244 9
2020-12-31 193 -372 -375 11
2019-12-31 121 -386 -392 11
DB:8AP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 94 -304 -346
2018-09-30 74 -305 -343
2018-06-30 70 -319 -325
2018-03-31 41 -310 -339
2017-12-31 43 -285 -315
2017-09-30 56 -262 -283
2017-06-30 53 -233 -269
2017-03-31 49 -17 -241
2016-12-31 70 39 -198
2016-09-30 53 59 -183
2016-06-30 50 83 -160
2016-03-31 56 -70 -136

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Agios Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Agios Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8AP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Agios Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.36 9.38 0.52 6.00
2022-12-31 0.40 4.94 -2.22 7.00
2021-12-31 -3.78 -1.88 -4.90 7.00
2020-12-31 -6.06 -3.74 -7.25 9.00
2019-12-31 -6.67 -5.88 -7.41 9.00
DB:8AP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -6.03
2018-09-30 -6.22
2018-06-30 -6.17
2018-03-31 -6.79
2017-12-31 -6.75
2017-09-30 -6.30
2017-06-30 -6.33
2017-03-31 -6.00
2016-12-31 -5.07
2016-09-30 -4.80
2016-06-30 -4.24
2016-03-31 -3.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Agios Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Agios Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Agios Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Agios Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Agios Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Agios Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Agios Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Agios Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Agios Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Agios Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8AP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 94.39 -346.03 114.15
2018-09-30 74.17 -342.52 105.00
2018-06-30 70.33 -324.99 91.35
2018-03-31 41.27 -339.33 80.85
2017-12-31 43.01 -314.67 71.12
2017-09-30 55.86 -282.87 63.79
2017-06-30 53.49 -268.57 58.19
2017-03-31 49.12 -241.44 54.70
2016-12-31 69.89 -198.47 50.71
2016-09-30 53.46 -182.61 45.52
2016-06-30 49.96 -160.03 43.59
2016-03-31 56.20 -135.97 39.88
2015-12-31 59.12 -117.73 35.99
2015-09-30 67.54 -103.77 32.31
2015-06-30 95.96 -59.81 27.55
2015-03-31 91.15 -46.21 22.79
2014-12-31 65.36 -53.50 19.12
2014-09-30 57.47 -39.22 16.33
2014-06-30 29.83 -54.67 13.70
2014-03-31 27.69 -46.79 11.37
2013-12-31 25.55 -43.57 9.93
2013-09-30 25.09 -49.08 7.78
2013-06-30 25.09 -40.19 6.82
2013-03-31 25.11 -29.89 6.94
2012-12-31 25.11 -27.29 7.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Agios Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Agios Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Agios Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Agios Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Agios Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Agios Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Agios Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Agios Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Agios Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Agios Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Agios Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Agios Pharmaceuticals Company Filings, last reported 3 months ago.

DB:8AP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 687.54 0.00 585.30
2018-09-30 760.21 0.00 669.89
2018-06-30 823.14 0.00 716.91
2018-03-31 865.59 0.00 782.45
2017-12-31 375.50 0.00 423.94
2017-09-30 449.81 0.00 507.93
2017-06-30 508.99 0.00 586.04
2017-03-31 307.38 0.00 479.76
2016-12-31 358.59 0.00 541.31
2016-09-30 401.45 0.00 579.10
2016-06-30 289.08 0.00 465.37
2016-03-31 332.37 0.00 312.89
2015-12-31 345.12 0.00 317.00
2015-09-30 375.66 0.00 352.37
2015-06-30 404.17 0.00 369.79
2015-03-31 426.82 0.00 344.71
2014-12-31 424.37 0.00 342.07
2014-09-30 207.75 0.00 219.97
2014-06-30 200.55 0.00 238.48
2014-03-31 121.34 0.00 162.27
2013-12-31 131.48 0.00 166.77
2013-09-30 142.60 0.00 194.96
2013-06-30 28.87 0.00 99.28
2013-03-31 37.12 0.00 115.75
2012-12-31 43.90 0.00 127.98
  • Agios Pharmaceuticals has no debt.
  • Agios Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Agios Pharmaceuticals has sufficient cash runway for 1.9 years based on current free cash flow.
  • Agios Pharmaceuticals has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 70.4% each year.
X
Financial health checks
We assess Agios Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Agios Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Agios Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Agios Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Agios Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Agios Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Agios Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8AP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8AP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Agios Pharmaceuticals has not reported any payouts.
  • Unable to verify if Agios Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Agios Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Agios Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Agios Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Agios Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Agios Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Agios Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Agios Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jackie Fouse
COMPENSATION $672,036
AGE 57
TENURE AS CEO 0.2 years
CEO Bio

Dr. Jacqualyn A. Fouse, also known as Jackie, Ph.D, serves as Director at Incyte Corporation since 2017. Dr. Fouse has served as Executive Chair of Dermavant Sciences, a biopharmaceutical company, since July 2017. She serves as a Director of Agios Pharmaceuticals, Inc. She serves as the Chief Executive Officer of Agios Pharmaceuticals, Inc. since February 1, 2019. She was elected to the Dick’s Sporting Goods, Inc.’s Board of Directors in September, 2010. She served as Director at Perrigo Company since 2012 until 2016. From September 2010 until June 2017, Dr. Fouse served in various capacities at Celgene Corporation, a biopharmaceutical company, serving as Strategic Advisor to the Management Executive Committee from April 2017 to June 2017, President and Chief Operating Officer from March 2016 to March 2017, President, Hematology and Oncology from August 2014 to February 2016, Executive Vice President and Chief Financial Officer from February 2012 to July 2014, and Senior Vice President and Chief Financial Officer from September 2010 to February 2012. Dr. Fouse has served as the Chief Financial Officer of Bunge Limited from July 2007 to September 2010, a global agribusiness and food company. From 2006 to 2007. Dr. Fouse was the Senior Vice President, Chief Financial Officer and Corporate Strategy, at Alcon, Inc. (“Alcon”), a global eye care company. In addition, from 2002, she was Alcon’s Senior Vice President and Chief Financial Officer. Previously, Dr. Fouse held a variety of senior finance positions at Alcon and its then majority owner Nestlé SA. Dr. Fouse earned a B.A. Ph.D. and M.A. in Economics from the University of Texas at Arlington.

CEO Compensation
  • Insufficient data for Jackie to compare compensation growth.
  • Jackie's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Agios Pharmaceuticals management team in years:

2.6
Average Tenure
62
Average Age
  • The tenure for the Agios Pharmaceuticals management team is about average.
Management Team

David Schenkein

TITLE
President & Executive Chairman
COMPENSATION
$6M
AGE
61

Jackie Fouse

TITLE
CEO & Director
COMPENSATION
$672K
AGE
57
TENURE
0.2 yrs

Lewis Cantley

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
$334K
AGE
69

Andrew Hirsch

TITLE
CFO & Head of Corporate Development
COMPENSATION
$2M
AGE
47
TENURE
2.6 yrs

Scott Biller

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
62
TENURE
8.6 yrs

Chris Bowden

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
57
TENURE
4.9 yrs

Tak Mak

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
72

Craig Thompson

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
65

Michael Su

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
62

Carman Alenson

TITLE
Principal Accounting Officer and VP of Accounting
TENURE
2.4 yrs
Board of Directors Tenure

Average tenure and age of the Agios Pharmaceuticals board of directors in years:

1.9
Average Tenure
62
Average Age
  • The average tenure for the Agios Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Schenkein

TITLE
President & Executive Chairman
COMPENSATION
$6M
AGE
61
TENURE
0.2 yrs

Jackie Fouse

TITLE
CEO & Director
COMPENSATION
$672K
AGE
57
TENURE
1.3 yrs

Lewis Cantley

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
$334K
AGE
69

Tak Mak

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
72

Craig Thompson

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
65

Michael Su

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
62

Paul Clancy

TITLE
Director
COMPENSATION
$355K
AGE
56
TENURE
5.6 yrs

Kaye Foster-Cheek

TITLE
Independent Director
COMPENSATION
$357K
AGE
58
TENURE
4.3 yrs

David Scadden

TITLE
Independent Director
COMPENSATION
$825K
AGE
64
TENURE
1.9 yrs

Pier Pandolfi

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Feb 19 Sell Carman Alenson Individual 28. Sep 18 28. Sep 18 -152 €65.80 €-10,002
13. Sep 18 Sell John Maraganore Individual 11. Sep 18 11. Sep 18 -13,555 €63.70 €-850,930
X
Management checks
We assess Agios Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Agios Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Details
Name: Agios Pharmaceuticals, Inc.
8AP
Exchange: DB
Founded: 2007
$2,926,782,137
58,395,419
Website: http://www.agios.com
Address: Agios Pharmaceuticals, Inc.
88 Sidney Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AGIO Common Stock Nasdaq Global Select US USD 24. Jul 2013
DB 8AP Common Stock Deutsche Boerse AG DE EUR 24. Jul 2013
LSE 0HB0 Common Stock London Stock Exchange GB USD 24. Jul 2013
Number of employees
Current staff
Staff numbers
482
Agios Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:59
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.